健友股份(603707.SH)获“注射用替加环素”药品注册证书

智通财经APP讯，健友股份(603707.SH)发布公告，公司于近日收到国家药品监督管理局(以下简称“国家药监局”)关于核准签发注射用替加环素(规格：50mg)药品注册证书的通知(药品批准文号：国药准字H20223221)。

据悉，注射用替加环素是第一个甘氨酰环素类抗生素，是四环素类抗生素的半合成衍生物。临床用于18岁以上患者在下列情况下由特定细菌的敏感菌株所致感染的治疗：复杂性腹腔内感染、复杂皮肤及软组织感染、社区获得性肺炎。

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.